跳至主要内容
临床试验/NCT00329485
NCT00329485终止不适用

The Effect of Ribose on B-Type Natriuretic Peptide Levels in Congestive Heart Failure Patients

Valen Labs1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2006年6月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
终止
发起方
入组人数
120
试验地点
1
主要终点
Demonstrate a significant reduction in serial BNP values over 3 months while on ribose supplementation

研究概览

简要总结

The purpose of this research study is to test the effectiveness of CORvalen, a medical food, to increase cellular energy sufficiently to change or modify BNP levels in congestive heart failure patients.

详细描述

B-type natriuretic peptide (BNP), is a blood test commonly used to track the progress of congestive heart failure. CORvalen, a medical food, contains D-Ribose (ribose), a natural substance that has been shown to improve the amount of energy compounds at the cellular level. Congestive heart failure has been associated with a reduced level of high-energy compounds. One researcher has called them an "energy starvation" in congestive heart failure. This study will try to assess if increasing the amount of these energy compounds is sufficient to improve BNP levels. Approximately 120 symptomatic congestive heart failure patients will participate in this 3 month study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Symptomatic adults, M/F, between 18 and 80 years of age
  • •BNP levels equal to or greater than 300 pg/ml.
  • •Primary or secondary diagnosis of congestive heart failure at the time of admission (any NYHA Class)
  • •Diagnosis of congestive heart failure for at least 3 months
  • •Able to perform 6 minute hall walk
  • •No therapeutic pharmaceutical class changes for at least 1 month
  • •Provide informed consent
  • •A 30-day washout period must be achieved for any patient involved in a previous clinical study.
  • •Insulin dependent diabetes (Type I)
  • •History of obstructive valvular disease
  • •History of pulmonary hypertension within the last 3 months
  • •History of hypertrophic or alcoholic cardiomyopathy
  • •History of restrictive cardiomyopathy
  • •History of reversible cardiomyopathy
  • •History of non-compliance
  • •Pregnancy
  • •Current enrollment in any other clinical study

排除标准

  • 未提供

结局指标

主要结局

Demonstrate a significant reduction in serial BNP values over 3 months while on ribose supplementation

次要结局

  • Demonstrate significant improvement in serial six minute hall walks while on ribose supplementation
  • Demonstrate significant improvement in quality of life as measured by the Minnesota, Living with Heart Failure Questionnaire.

研究者

发起方
Valen Labs
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验